MX2012007273A - Pteridinonas como inhibidores de la quinasa tipo polo. - Google Patents

Pteridinonas como inhibidores de la quinasa tipo polo.

Info

Publication number
MX2012007273A
MX2012007273A MX2012007273A MX2012007273A MX2012007273A MX 2012007273 A MX2012007273 A MX 2012007273A MX 2012007273 A MX2012007273 A MX 2012007273A MX 2012007273 A MX2012007273 A MX 2012007273A MX 2012007273 A MX2012007273 A MX 2012007273A
Authority
MX
Mexico
Prior art keywords
pteridinones
polo
kinase
inhibitors
compounds
Prior art date
Application number
MX2012007273A
Other languages
English (en)
Inventor
Simeon Bowers
Roy K Hom
Anh P Truong
Xiaocong Michael Ye
Danielle L Aubele
Jennifer Sealy
Yong-Liang Zhu
Robert A Galemmo Jr
Dean Richard Artis
R J Effrey Neitz
Marc Adler
John P Anderson
Paul Beroza
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of MX2012007273A publication Critical patent/MX2012007273A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/12—Heterocyclic compounds containing pteridine ring systems containing pteridine ring systems condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención provee compuestos que tienen una estructura de acuerdo con la Fórmula (I) o una sal o solvato de la misma, en donde el anillo A, X, R1, R2, R3, R4, R5 y R6, son definidos en la presente. La invención provee además composiciones farmacéuticas que incluyen los compuestos de la invención y métodos para formar y usar los compuestos y composiciones de la invención, v.gr., en el tratamiento y prevención de varios trastornos, tales como enfermedad de Parkinson.
MX2012007273A 2009-12-23 2010-12-21 Pteridinonas como inhibidores de la quinasa tipo polo. MX2012007273A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28998009P 2009-12-23 2009-12-23
US40479710P 2010-10-08 2010-10-08
PCT/US2010/061535 WO2011079114A1 (en) 2009-12-23 2010-12-21 Pteridinones as inhibitors of polo - like kinase

Publications (1)

Publication Number Publication Date
MX2012007273A true MX2012007273A (es) 2012-12-17

Family

ID=43530443

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007273A MX2012007273A (es) 2009-12-23 2010-12-21 Pteridinonas como inhibidores de la quinasa tipo polo.

Country Status (15)

Country Link
US (5) US8445503B2 (es)
EP (1) EP2516441B1 (es)
JP (1) JP2013515734A (es)
KR (1) KR20120120252A (es)
CN (1) CN102762568A (es)
AU (1) AU2010336509A1 (es)
BR (1) BR112012015714A2 (es)
CA (1) CA2783258A1 (es)
IL (1) IL220563A0 (es)
MX (1) MX2012007273A (es)
PH (1) PH12012501122A1 (es)
RU (1) RU2012131124A (es)
SG (1) SG181908A1 (es)
WO (2) WO2011079114A1 (es)
ZA (1) ZA201204136B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501581A1 (en) * 2010-02-03 2012-10-22 Signal Pharm Llc Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
WO2012048129A2 (en) 2010-10-08 2012-04-12 Elan Pharmaceuticals, Inc. Inhibitors of polo-like kinase
WO2012148548A1 (en) * 2011-02-25 2012-11-01 Takeda Pharmaceutical Company Limited N-substituted oxazinopteridines and oxazinopteridinones
JP2015512409A (ja) * 2012-03-26 2015-04-27 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 脊髄性筋萎縮症用治療剤としての４−アミノピリジン
CN104837832B (zh) * 2012-10-05 2019-04-26 里格尔药品股份有限公司 Gdf-8抑制剂
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
JP6052527B2 (ja) * 2013-02-21 2016-12-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノンｉ
CN105339008A (zh) 2013-04-17 2016-02-17 西格诺药品有限公司 用于治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯酰胺的组合疗法
MX368286B (es) 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
JP6382945B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
EP2986321A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
MX393164B (es) 2013-04-17 2025-03-21 Signal Pharm Llc Formulaciones farmacéuticas, proceso, formas sólidas y métodos de uso relacionados con 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-ii)piridin-3-ii)-3,4-dihidropirazino[2,3-b]pirazin-2(1h)-ona.
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
HK1221150A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用二氢吡嗪并-吡嗪类对癌症的治疗
NZ629486A (en) 2013-05-29 2017-11-24 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
CN103819400B (zh) * 2013-09-16 2016-05-04 江西师范大学 一种多组分反应合成具有不对称结构1.4-二氢吡啶及其衍生物的方法
RU2550346C2 (ru) * 2013-09-26 2015-05-10 Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EP3131551A4 (en) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
CN104402823B (zh) * 2014-11-05 2016-03-23 上海浩登材料科技有限公司 一种1，2-二甲基咪唑的制备方法
CN104496906B (zh) * 2014-11-05 2016-03-23 上海浩登材料科技有限公司 一种咪唑的制备方法
WO2017002089A1 (en) 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
KR101796779B1 (ko) 2015-12-22 2017-11-10 한국화학연구원 다이하이드로프테리딘-온 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
US10138222B2 (en) * 2016-09-15 2018-11-27 Boehringer Ingelheim International Gmbh Substituted benzamides as RIPK2 inhibitors
CN106543185B (zh) * 2016-11-10 2017-12-15 吉林大学 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
MX2020008959A (es) 2018-02-28 2020-10-05 Novartis Ag Derivados de 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7h -pirrolo[1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona y compuestos relacionados como inhibidores de la replicacion del ortomixovirus para el tratamiento de influenza.
CN108794493B (zh) * 2018-04-28 2020-04-24 北京施安泰医药技术开发有限公司 四氢吡咯并[2,1-h]蝶啶-6(5H)-酮衍生物、其药物组合物、制备方法和应用
WO2020076728A1 (en) 2018-10-08 2020-04-16 Takeda Pharmaceutical Company Limited SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
WO2023083286A1 (en) 2021-11-12 2023-05-19 Insilico Medicine Ip Limited Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
PE20241234A1 (es) * 2021-11-12 2024-06-19 Insilico Medicine Ip Ltd Inhibidores de molecula pequena de proteasa especifica de ubiquitina 1 (usp1) y usos de los mismos
CN114369064B (zh) * 2022-01-10 2023-12-19 北京莱瑞森医药科技有限公司 一种西地那非中间体的制备方法
CN114671810B (zh) * 2022-03-21 2024-03-22 济南鸿湾生物技术有限公司 一种咪唑苯脲的制备方法
CN117003757A (zh) * 2022-05-07 2023-11-07 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为usp1抑制剂

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2029651C (en) * 1989-11-17 2000-06-06 David D. Davey Tricyclic pteridinones and a process for their preparation
US6025489A (en) * 1989-11-17 2000-02-15 Schering Aktiengesellschaft Tricyclic pteridinones and a process for their preparation
US6129387A (en) * 1999-07-06 2000-10-10 Moore North America, Inc. Pressure sensitive library card holder
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
EP1427730B1 (de) 2001-09-04 2006-07-12 Boehringer Ingelheim Pharma GmbH & Co.KG Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
EP1312365A1 (de) * 2001-11-20 2003-05-21 Jenapharm GmbH & Co. KG Pteridinone zur Behandlung der erektilen Dysfunktion
UA80743C2 (en) * 2003-02-26 2007-10-25 Boehringer Ingelheim Pharma Dihydropteridinones, method for the production and use thereof in the form of drugs
WO2005079799A1 (en) 2004-02-13 2005-09-01 Glaxo Group Limited 4-acyl-piperazines as anti-viral agents
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
AR060432A1 (es) 2006-04-12 2008-06-18 Vertex Pharma Tetrahidropteridinas utiles como inhibidores de las proteinas quinasas
EP2029599A1 (en) 2006-05-19 2009-03-04 Astra Zeneca AB Dihydropteridine compounds as anti proliferative agents
MX2009004019A (es) 2006-10-19 2009-06-19 Signal Pharm Llc Compuestos heteroarilo, composiciones de los mismos, y uso de los mismos como inhibidores de proteina cinasa.
CA2672612A1 (en) 2006-12-14 2008-06-26 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
JP2010208945A (ja) 2007-06-01 2010-09-24 Mitsubishi Tanabe Pharma Corp 複素環化合物
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
US8461149B2 (en) 2007-08-15 2013-06-11 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
JP2009073743A (ja) * 2007-09-19 2009-04-09 Taiho Yakuhin Kogyo Kk 新規な縮合環式ピリミジン化合物又はその塩、及びその医薬組成物
CN103122001A (zh) 2007-09-25 2013-05-29 武田药品工业株式会社 Polo样激酶抑制剂
JP5400791B2 (ja) 2007-12-04 2014-01-29 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ジヒドロプテリジン−６−オン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用
EP2247748A2 (en) * 2008-02-13 2010-11-10 Elan Pharma International Limited Alpha-synuclein kinase
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
GB0807451D0 (en) * 2008-04-24 2008-05-28 Chroma Therapeutics Ltd Inhibitors of PLK
WO2010077613A1 (en) 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulators of toll-like receptors
CN101544642A (zh) * 2009-03-12 2009-09-30 山东省医药工业研究所 4-蝶啶氨类化合物及其制备和用途
AR077974A1 (es) 2009-08-28 2011-10-05 Takeda Pharmaceutical Compuestos de hexahidrooxazinopterina para uso como inhibidores de mtor
CN102020643A (zh) 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
US20120329803A1 (en) 2010-02-17 2012-12-27 Boehringer Ingelheim International Gmbh Dihydropteridinones, method for production and use thereof

Also Published As

Publication number Publication date
ZA201204136B (en) 2013-08-28
PH12012501122A1 (en) 2012-10-29
US20110212942A1 (en) 2011-09-01
EP2516441B1 (en) 2015-01-21
CA2783258A1 (en) 2011-06-30
BR112012015714A2 (pt) 2017-04-25
SG181908A1 (en) 2012-08-30
IL220563A0 (en) 2012-08-30
AU2010336509A1 (en) 2012-07-19
US8541418B2 (en) 2013-09-24
JP2013515734A (ja) 2013-05-09
RU2012131124A (ru) 2014-01-27
US20130231335A1 (en) 2013-09-05
EP2516441A1 (en) 2012-10-31
US20110207716A1 (en) 2011-08-25
WO2011079118A1 (en) 2011-06-30
US20130331376A1 (en) 2013-12-12
WO2011079114A1 (en) 2011-06-30
CN102762568A (zh) 2012-10-31
US20150126502A1 (en) 2015-05-07
KR20120120252A (ko) 2012-11-01
US8445503B2 (en) 2013-05-21

Similar Documents

Publication Publication Date Title
MX2012007273A (es) Pteridinonas como inhibidores de la quinasa tipo polo.
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
WO2012048129A3 (en) Inhibitors of polo-like kinase
TW200726753A (en) 2,4-diamino-pyrimidines as aurora inhibitors
IN2012DN01233A (es)
MY147390A (en) Substituted isoindoles as bace inhibitors and their use
MX2011008276A (es) Inhibidores de quinasa jun n-terminal.
SG179120A1 (en) Novel compounds
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
MX2009000333A (es) Pirrilopirimidinas para composiciones farmaceuticas.
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
MX2011012337A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades.
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
HK1206597A1 (en) Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
TW200806300A (en) New therapeutic combinations for the treatment of depression
UA94944C2 (ru) 2,4-диаминопиримидины как ингибиторы киназ, которые принимают участие в регуляции клеточного цикла
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
TW200630374A (en) Thiazolyldihydroindazoles

Legal Events

Date Code Title Description
FG Grant or registration